Cross-sectional analysis of germline BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary breast/ovarian cancer

Cancer Science

Volumn 99, Issue 10, 2008, Pages 1967-1976

  Sugano, Kokichi ^a,f,g   Nakamura, Seigo ⁱ   Ando, Jiro ^a   Takayama, Shin ^a,e   Kamata, Hiroyuki ^a   Sekiguchi, Isao ^a   Ubukata, Megumi ^a   Kodama, Tetsuro ^a,g   Arai, Masami ^d   Kasumi, Fujio ^d   Hirai, Yasuo ^d   Ikeda, Tadashi ^e   Jinno, Hiromitsu ^e   Kitajima, Masaki ^e   Aoki, Daisuke ^e   Hirasawa, Akira ^e   Takeda, Yuko ^e,f   Yazaki, Kumiko ^f   Fukutomi, Takashi ^g,l   Kinoshita, Takayuki ^g   Tsunematsu, Ryuichiro ^g   Yoshida, Teruhiko ^g,h   Izumi, Masako ^g   Umezawa, Shino ^g   Yagata, Hiroshi ⁱ   Komatsu, Hiroko ^i,j   Arimori, Naoko ^i,j   Matoba, Noriko ^i,j   Gondo, Nobuhisa ^k   Yokoyama, Shiro ^k   Miki, Yoshio ^b,c   more..

^a TOCHIGI CANCER CENTER   (Japan)

^b CANCER INSTITUTE   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d CANCER INSTITUTE HOSPITAL   (Japan)

^e KEIO UNIVERSITY   (Japan)

^f KEIO UNIVERSITY HOSPITAL   (Japan)

^g NATIONAL CANCER CENTER HOSPITAL   (Japan)

^h NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

ⁱ ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^j ST LUKE'S INTERNATIONAL UNIVERSITY   (Japan)

^k FALCO Biosystems   (Japan)

^l AICHI MEDICAL UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CANCER SUSCEPTIBILITY; CROSS-SECTIONAL STUDY; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC COUNSELING; HEREDITY; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OVARY CANCER; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; VALIDATION PROCESS;

BREAST NEOPLASMS; CONFIDENCE INTERVALS; CROSS-SECTIONAL STUDIES; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC SCREENING; GERM-LINE MUTATION; HUMANS; INCIDENCE; JAPAN; ODDS RATIO; OVARIAN NEOPLASMS; PREVALENCE; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA;

EID: 54949127524     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00944.x     Document Type: Article

References (28)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancerbase No. 5, Version 2.0. Lyon, France: IARC Press, 2004.
2. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: Collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 2001; 358: 1389-99.
3. Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 1994; 266: 66-71.
4. Wooster R, Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789-92.
5. Frank TS, Critchfield GC. Identifying and managing hereditary risk of breast and ovarian cancer. Clin Perinatol 2001; 28: 395-406.
6. Frank TS, Deffenbaugh AM, Reid JE et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: Analysis of 10,000 individuals. J Clin Oncol 2002; 20: 1480-90.
7. Inoue R, Fukutomi T, Ushijima T, Matsumoto Y, Sugimura T, Nagao M. Germline mutation of BRCA1 in Japanese breast cancer families. Cancer Res 1995; 55: 3521-4.
8. Katagiri T, Emi M, Ito I et al. Mutations in the BRCA1 gene in Japanese breast cancer patients. Hum Mutat 1996; 7: 334-9.
9. Noguchi S, Kasugai T, Miki Y, Fukutomi T, Emi M, Nomizu T. Clinicopathologic analysis of BRCA1- or BRCA2-associated hereditary breast carcinoma in Japanese women. Cancer 1999; 85: 2200-5.
10. Ikeda N, Miyoshi Y, Yoneda K et al. Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families. Int J Cancer 2001; 91: 83-8.
11. Sekine M, Nagata H, Tsuji S et al. Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: Two common founder mutations of BRCA1 in Japanese population. Clin Cancer Res 2001; 7: 3144-50.
12. Kawahara M, Sakayori M, Shiraishi K et al. Identification and evaluation of 55 genetic variations in the BRCA1 and the BRCA2 genes of patients from 50 Japanese breast cancer families. J Hum Genet 2004; 49: 391-5.
13. Szabo C, Masiello A, Ryan JF, Brody LC. The breast cancer information core; database design, structure, and scope. Hum Mutat 2000; 16: 123-31.
14. Kauff ND, Satagopan JM, Robson ME et al. Risk-reducing salpingo-oophorectomy (RRSO) in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346: 1609-15.
15. Uyei A, Peterson SK, Erlichman J et al. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: A single-institution study. Cancer 2006; 107: 2745-51.
16. Metcalfe K, Lynch HT, Ghadirian P et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004; 22:2328-35.
17. McLaughlin JR, Risch HA, Lubinski J et al. Hereditary Ovarian Cancer Clinical Study Group. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: A case-control study. Lancet Oncol 2007; 8: 26-34.
18. Petrij-Bosch A, Peelen T, van Vliet M et al. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet 1997; 17: 341-5.
19. The BRCA1 Exon 13 Duplication Screening Group. The Exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse population. Am J Hum Gen 2000; 67: 207-12.
20. Rohlfs EM, Puget N, Graham ML et al. An Alu-mediated 7.1 kb deletion of BRCA1 exons 8 and 9 in breast and ovarian cancer families that results in alternative splicing of exon 10. Genes Chromosomes Cancer 2000; 28: 300-7.
21. Ward BD, Hendrickson BC, Judkins T et al. A multi-exonic BRCA1 deletion identified in multiple families through single nucleotide polymorphism haplotype pair analysis and gene amplification with widely dispersed primer sets. J Mol Diagn 2005; 7: 139-42.
22. Antonarakis SE and the Nomenclature Working Group. Recommendations for a nomenclature system for human gene mutations. Hum Mutat, 1998; 11: 1-3.
23. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002; 30: E57.
24. Bunyan DJ, Eccles DM, Sillibourne J et al. Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification. Br J Cancer 2004; 9: 1155-9.
25. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-48.
26. Lichtenstein P, Holm NV, Verkasalo PK et al. Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343: 78-85.
27. John EM, Miron A, Gong G et al. Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA 2007; 298: 2869-76.
28. Metcalfe KA, Lubinski J, Ghadirian P et al. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: The Hereditary Breast Cancer Clinical Study Group. J Clin Oncol 2008; 26: 1093-7.